Robust central reduction of amyloid-β in humans with an orally available, non-peptidic β-secretase inhibitor. [electronic resource]
- The Journal of neuroscience : the official journal of the Society for Neuroscience Nov 2011
- 16507-16 p. digital
Publication Type: Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
1529-2401
10.1523/JNEUROSCI.3647-11.2011 doi
Adult Alzheimer Disease--cerebrospinal fluid Amyloid Precursor Protein Secretases--analysis Amyloid beta-Peptides--cerebrospinal fluid Amyloid beta-Protein Precursor--cerebrospinal fluid Analysis of Variance Animals Aspartic Acid Endopeptidases--analysis Cells, Cultured Cerebral Cortex--cytology Crystallography--methods Disease Models, Animal Dogs Dose-Response Relationship, Drug Embryo, Mammalian Enzyme Inhibitors--blood Enzyme-Linked Immunosorbent Assay--methods Female Humans Male Mice Mice, Transgenic Middle Aged Models, Chemical Mutation--genetics Neurons--drug effects Peptide Fragments--cerebrospinal fluid Pyrimidines--pharmacology Rats Rats, Sprague-Dawley Thiazines--pharmacology Time Factors Young Adult